EUNICE RAMOS: Open Payments
NPI 1750997789 · PARAMUS, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,215 in 81 payments from 12 companies in 2025. Trend: 2023 $132 · 2024 $507 · 2025 $2,215
Food & beverage: $2,215
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $619 |
| Otsuka America Pharmaceutical, Inc. | 12 | $348 |
| Neurocrine BioSciences, Inc. | 7 | $341 |
| Vanda Pharmaceuticals Inc. | 8 | $233 |
| Alkermes, Inc. | 3 | $166 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $139 |
| Almatica Pharma LLC | 9 | $135 |
| Lundbeck LLC | 5 | $92 |
| Supernus Pharmaceuticals, Inc. | 5 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
Products named: VRAYLAR, REXULTI, INGREZZA, FANAPT, CAPLYTA, LOREEV XR, LYBALVI, Qelbree.
Industry payments across NJ — which companies pay providers there.
